List of Excipients in Branded Drug DOTAREM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Guerbet LLC	DOTAREM	gadoterate meglumine	67684-2000	WATER

DOTAREM Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Dotarem is a gadolinium-based MRI contrast agent containing gadoterate meglumine at 0.5 mmol/mL. Its U.S. formulation is deliberately simple: gadoterate meglumine in water for injection, with meglumine functioning as the counterion in the chelated active ingredient rather than as a conventional performance excipient. The main commercial opportunities are in manufacturing efficiency, container-closure systems, ready-to-use presentation, supply resilience, and differentiated imaging workflows. Conventional excipient substitution has limited value because the product’s safety, osmolality, stability, sterility, and physicochemical profile are tightly linked to the gadoterate meglumine complex itself.

What is the Dotarem formulation and which excipients does it contain?

Dotarem contains gadoterate meglumine, water for injection, and no preservative in the marketed single-dose formulation.

Formulation attribute	Dotarem profile
Active ingredient	Gadoterate meglumine
Gadolinium concentration	0.5 mmol/mL
Equivalent gadolinium content	0.2793 g gadolinium per mL
Counterion	Meglumine
Vehicle	Water for injection
Preservative	None in the single-dose presentation
Route	Intravenous
Dosage form	Sterile injectable solution
Typical dose	0.2 mL/kg, equivalent to 0.1 mmol/kg
pH	Approximately 6.5 to 8.0
Osmolality	Higher than plasma, consistent with a gadolinium-based contrast solution

The U.S. prescribing information identifies gadoterate meglumine as the active component and water for injection as the inactive component. Meglumine is chemically incorporated into the marketed gadoterate meglumine salt and should not be treated as a freely replaceable formulation excipient. (Guerbet, 2023; U.S. Food and Drug Administration [FDA], 2013)

Why is the excipient list so short?

Gadoterate is a macrocyclic gadolinium complex with high thermodynamic and kinetic stability. The product does not require a surfactant, antimicrobial preservative, co-solvent, or buffering system in its standard single-dose format. A minimal formulation reduces the number of variables affecting:

• Gadolinium complex integrity
• Free gadolinium levels
• pH drift
• Metal contamination
• Particulate formation
• Container compatibility
• Injection tolerability
• Sterilization and shelf-life validation

The absence of conventional excipients does not mean the formulation is easy to replicate. The active salt, aqueous processing, metal-control strategy, fill-finish process, and container system determine product quality.

What excipient strategies are commercially relevant for Dotarem?

The strongest opportunities are adjacent to the formulation rather than substitutions for water or meglumine.

1. Container-closure optimization

Single-dose contrast agents are distributed in glass vials, polymer containers, syringes, and injector-compatible formats. Commercial opportunities include:

• Low-extractables and low-leachables polymer containers
• Reduced tungsten and silicone-oil exposure
• Improved stopper and plunger compatibility
• Light-protective packaging
• Higher-volume presentations for automated injectors
• Unit-dose syringes for outpatient imaging centers

For a low-excipient injectable, the container can become a material source of contamination or particulate risk. Suppliers that can demonstrate low metal transfer, low particulate generation, and compatibility with gadoterate solutions have a stronger commercial position than suppliers offering a new soluble excipient.

2. Ready-to-use syringe systems

Ready-to-use presentations can reduce preparation time and medication errors in radiology departments. The value proposition includes:

• Lower pharmacy compounding labor
• Fewer vial transfers
• Simplified dose verification
• Better integration with automated injectors
• Lower residual drug waste
• More consistent workflow in high-volume MRI centers

The commercial barrier is not simply syringe filling. The presentation must meet requirements for sterility, extractables, dose accuracy, siliconization, terminal sterilization or aseptic processing, and compatibility with approved injector systems.

3. Waste-reduction formats

Gadoterate is administered according to body weight, while common commercial packages may not match the calculated patient dose. This creates residual-volume waste. Opportunities include:

• Smaller unit doses for pediatric and low-body-weight patients
• Multi-size syringe portfolios
• Dose-banded presentations
• Injector systems that minimize dead volume
• Closed-transfer systems that reduce discarded residual product

A smaller container can improve utilization but increases packaging, labeling, and inventory complexity. The economic opportunity is strongest where contrast volumes are high and labor or waste costs are material.

4. Stability-enhancing manufacturing controls

A formulation may remain compositionally simple while requiring advanced control of the manufacturing environment. Commercially relevant technologies include:

• High-purity water systems
• Trace-metal control
• In-line conductivity and pH monitoring
• Low-shear mixing
• Closed aseptic transfer
• Automated visual inspection
• Container-closure integrity testing
• Real-time particulate monitoring

These capabilities can support contract manufacturing, technology-transfer, and licensing opportunities even when no new excipient is introduced.

What formulations are protected by Dotarem-related intellectual property?

The commercially important IP is likely to center on the gadoterate complex, production process, sterile injectable presentation, and device compatibility rather than a broad excipient patent.

IP category	Relevance to Dotarem	Commercial significance
Gadoterate complex chemistry	Defines the active chelate and salt form	High, but legacy chemistry is mature
Manufacturing process	Controls chelation, impurity profile, metal residues, and yield	High for generic and contract manufacturers
Injectable formulation	Covers concentration, pH, purity, and stability parameters	Moderate to high depending on claim scope
Container closure	Covers compatibility and delivery presentation	Moderate
Automated injector interface	Can support device or presentation differentiation	Moderate
Method of use	MRI diagnostic imaging indications	Generally weaker after regulatory exclusivity expires
Excipient composition	Limited because the formulation uses few conventional excipients	Low as a standalone opportunity

A patent analysis should distinguish active patents from expired foundational patents, unlisted manufacturing know-how, and regulatory protection. A simple formulation composition does not eliminate process-IP risk. A competitor may avoid an expired formulation claim and still face development costs associated with impurity control, scale-up, aseptic filling, and container compatibility.

When does Dotarem lose exclusivity and what is the generic-entry position?

Dotarem received initial U.S. approval in 2013. The product is a small-molecule, nonbiologic injectable drug, so biosimilar exclusivity does not apply. Generic competitors would generally pursue an abbreviated new drug application rather than a biosimilar application. (FDA, 2013; FDA, 2024a)

Regulatory exclusivity

The principal U.S. regulatory protections associated with a 2013 new drug application have elapsed or are no longer the primary commercial barrier. The relevant issues now are:

• Whether FDA has approved a therapeutically equivalent gadoterate product
• Whether any listed patents remain enforceable
• Whether patents are listed for the relevant NDA
• Whether a generic applicant has submitted a Paragraph IV certification
• Whether litigation has triggered a 30-month stay
• Whether pediatric or other statutory extensions apply

The Orange Book must be checked for the current patent and exclusivity record associated with the applicable Dotarem NDA. The Orange Book distinguishes approved products, therapeutic-equivalence evaluations, patents, and exclusivity. It does not capture every manufacturing patent, trade secret, device right, or foreign patent. (FDA, 2024b)

Paragraph IV exposure

A Paragraph IV challenge would target a listed patent that the applicant asserts is invalid, unenforceable, or not infringed. For Dotarem, the most commercially meaningful potential targets would be:

• Composition claims covering gadoterate meglumine
• Concentration and injectable-solution claims
• Stability claims
• Container or delivery-system claims
• Method-of-use claims with meaningful remaining term

Because gadoterate meglumine is an established active ingredient, a Paragraph IV strategy would likely focus on residual formulation, process, or presentation patents rather than basic molecular novelty. The value of a challenge would depend on whether the listed patent blocks the reference product or only a narrow presentation.

Is Dotarem subject to biosimilar risk?

No. Dotarem is a small-molecule gadolinium contrast agent, not a biologic. The relevant competitive threat is generic or alternative-contrast entry, not biosimilar substitution.

The absence of biosimilar risk does not eliminate competitive pressure. MRI centers may substitute among macrocyclic and linear gadolinium agents based on:

• MRI indication
• Gadolinium retention profile
• Renal-risk policies
• Formulary preference
• Price
• Injector compatibility
• Supply availability
• Hospital purchasing contracts

Gadoterate is a macrocyclic, ionic gadolinium agent. Competing products include gadobutrol, gadoteridol, gadobenate, and gadoxetate products, although these agents are not automatically therapeutically interchangeable for every imaging use.

How does Dotarem compare with competing MRI contrast agents?

Product	Active agent	Structural class	Main competitive issue
Dotarem	Gadoterate meglumine	Macrocyclic, ionic	Established safety profile and broad MRI use
Clariscan	Gadoterate meglumine	Macrocyclic, ionic	Direct active-ingredient competition
Gadavist/Gadovist	Gadobutrol	Macrocyclic, nonionic	Strong hospital and injector presence
ProHance	Gadoteridol	Macrocyclic, nonionic	Long-established MRI positioning
MultiHance	Gadobenate dimeglumine	Linear, ionic	Alternative imaging characteristics
Eovist/Primovist	Gadoxetate disodium	Linear, ionic, hepatobiliary	Liver-specific imaging differentiation

Dotarem’s closest product-level competition is Clariscan because both contain gadoterate meglumine. Competition from other gadolinium agents is broader and depends on clinical protocol, indication, procurement policy, and institutional preference.

What FDA regulatory pathway applies to a Dotarem generic?

A conventional generic applicant would generally use an ANDA pathway if the product can meet the relevant requirements for sameness, quality, performance, and therapeutic equivalence. Key CMC areas include:

• Same active moiety and salt form
• Same strength and route
• Sterile injectable quality
• Comparable pH and osmolality
• Comparable impurity profile
• Control of free gadolinium and related substances
• Container-closure compatibility
• Stability under approved storage conditions
• Particulate and bacterial-endotoxin control
• Demonstrated bioequivalence or applicable waiver rationale

A 505(b)(2) pathway could be relevant for a materially different presentation, delivery system, or formulation that does not fit a conventional ANDA approach. A new syringe, injector-linked device, preservative-containing multidose system, or materially different concentration could create a more complex regulatory route.

What manufacturing and IP barriers limit generic entry?

The largest barriers are technical and operational:

1. Chelation and impurity control. The process must consistently produce the intended gadolinium complex with low levels of unchelated metal and related impurities.

2. Raw-material quality. DOTA-related intermediates, gadolinium inputs, meglumine, and water systems require tight specifications.

3. Sterile fill-finish capacity. Contrast-agent demand favors high-volume facilities with validated aseptic or terminal-sterilization processes.

4. Container compatibility. Packaging components can introduce particulates, metals, silicone, or organic extractables.

5. Supply security. Gadolinium-containing products depend on specialized raw materials and validated suppliers.

6. Device integration. Injector-compatible syringes and vials may require separate design, testing, and commercial agreements.

These barriers support contract development and manufacturing opportunities even when conventional excipient innovation is limited.

What licensing and commercial opportunities exist around Dotarem?

The most credible deal opportunities are:

Opportunity	Potential partner	Value driver
Generic gadoterate development	Specialty injectable company	Low-complexity excipient profile with technical CMC barriers
Ready-to-use syringes	Device manufacturer or radiology supplier	Labor reduction and injector compatibility
Contract fill-finish	Sterile injectable CMO	High-volume production and global supply
Packaging technology	Polymer, glass, stopper, or syringe supplier	Extractables, leachables, and particulate control
Regional distribution	Imaging-product distributor	Hospital and outpatient MRI access
Waste-reduction systems	Injector manufacturer	Lower residual volume and improved workflow
Manufacturing know-how	API or finished-dose company	Process yield, purity, and scale-up

Direct licensing of a novel excipient is less attractive because Dotarem does not rely on a complex excipient system. A formulation-license transaction would have greater commercial logic if it included a new container, syringe, injector, stability platform, or manufacturing process.

What is the revenue exposure and competitive outlook for Dotarem?

Dotarem revenue is exposed to three forms of competition:

• Direct competition from gadoterate meglumine products
• Therapeutic substitution by other macrocyclic agents
• Procurement-driven price compression in hospital and outpatient imaging

The product’s revenue durability depends less on conventional patent exclusivity than on brand recognition, supply reliability, regulatory approvals, physician familiarity, distributor relationships, and purchasing contracts. Generic or authorized-generic entry would likely create price pressure first in institutional accounts, where tenders and formularies are influential.

A differentiated presentation could defend margin better than a simple vial. Pre-filled syringes, lower-waste formats, and validated injector compatibility create switching costs that a commodity injectable may not have.

Key Takeaways

• Dotarem uses a minimal formulation based on gadoterate meglumine and water for injection.
• Meglumine is part of the active salt and is not a conventional interchangeable excipient.
• The strongest commercial opportunities are in packaging, pre-filled syringes, injector integration, waste reduction, and sterile manufacturing.
• Dotarem has generic-entry exposure rather than biosimilar exposure.
• The principal IP risks are likely to involve residual formulation, process, container, and device claims rather than broad excipient claims.
• Generic development depends on control of free gadolinium, impurities, sterility, particulates, container compatibility, and supply continuity.
• Direct competition includes Clariscan and other macrocyclic gadolinium agents such as Gadavist and ProHance.
• A licensing strategy centered only on a new excipient has limited commercial logic. A combined formulation, packaging, device, and manufacturing package is more defensible.

FAQs

Does Dotarem contain sodium chloride?

The U.S. Dotarem formulation is identified as gadoterate meglumine in water for injection. Sodium chloride is not identified as a principal inactive ingredient in the U.S. label.

Can meglumine in Dotarem be replaced with another counterion?

A counterion change would create a different chemical form and could affect solubility, osmolality, stability, tolerability, and regulatory sameness. It would not be a routine excipient substitution.

Is Dotarem preservative-free?

The single-dose injectable presentation does not use a conventional antimicrobial preservative. This supports MRI workflow and reduces preservative-related compatibility concerns.

Can a generic company use the same excipients as Dotarem?

A generic company would normally seek the same active ingredient, strength, route, and relevant formulation characteristics. Water for injection is straightforward, but the gadoterate meglumine salt, impurity profile, stability, packaging, and sterile manufacturing process require separate validation.

Which Dotarem presentation has the greatest commercial opportunity?

Ready-to-use, injector-compatible pre-filled syringes and lower-waste unit-dose formats offer the clearest differentiation because they can reduce preparation labor, residual waste, and administration variability.

References

1. European Medicines Agency. (2023). Dotarem: EPAR product information. https://www.ema.europa.eu/

2. Food and Drug Administration. (2013). Dotarem (gadoterate meglumine) injection prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/

3. Food and Drug Administration. (2024a). Abbreviated new drug application submissions: Generic drugs. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

4. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

5. Guerbet. (2023). Dotarem gadoterate meglumine injection prescribing information. https://www.guerbet.com/